KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that it will host a conference call on Tuesday, August 12, 2014 at 8:30 a.m. EDT to discuss its financial and operational results for the second quarter ended June 30, 2014. The company will issue a press release reporting its results at approximately 7:00 a.m. EDT on August 12.
|Date:||Tuesday, August 12, 2014|
|Time:||8:30 a.m. (EDT)|
|Call-in Numbers:||(855) 465-0180 (U.S. and Canada)|
Please plan on accessing the conference call ten minutes prior to the scheduled start time. The conference call also will be broadcast live via the company's website by visiting the “Investors” section of www.trevenainc.com. A replay of the webcast will be available for two weeks starting shortly after the end of the call and can be accessed on the company’s website.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates in its portfolio, including from a preclinical program focused on central nervous system indications.